NEWS
Go back
ARCHIMED closes MED IV fund at €1.5 billion ($1.75 billion) hard cap, three times oversubscribed, in less than six months of fundraising
September
9,
2026
MED IV follows the €650 million ($750 million) MED III fund. It will pursue the series’ smallcap healthcare buyout strategy, while building a more diversified, global portfolio.
ARCHIMED, a global private equity specialist exclusively focused on healthcare, announces the final closing of the MED IV fund at its €1.5 billion ($1.75 billion) hard cap. Launched in January 2026 with an original target of €1.2 billion ($1.4 billion), the fund closed in less than six months and was three times oversubscribed, reflecting strong, sustained demand from existing and new investors.
“The momentum behind MED IV reflects investors’ confidence in our approach,” says Denis Ribon, Chairman and Managing Partner at ARCHIMED. “Investors like our healthcare specialization, top-decile DPI track-record [ratio of distributed to paid-in capital], our proven alpha-focused Playbook, the well-structured and scalable platform, and our transparent governance and stable ownership.”
MED IV’s investor base is global, loyal and expanding. The fund attracted a broad group of largely institutional limited partners, including pension funds, insurance companies and sovereign wealth funds, who believe ARCHIMED will reliably generate superior returns in healthcare. The process of opening ARCHIMED’s Abu Dhabi office in August 2026 further cemented relationships across the Middle East and Asia, contributing to the geographic diversification of the LP base.
” To achieve this success, we’ve seen strong acceleration in Asia, while building on long-standing partnerships with our European and North American investors,” says Baptiste Mélinon, Partner and Head of Investor Relations at ARCHIMED. Europe and North America represent 80% of MED IV’s investor base (equally split); the rest of the world accounts for the remainder.
Like its MED III predecessor, MED IV will invest primarily through majority control transactions alongside founders, families and management teams, in ARCHIMED’s prioritized healthcare sectors. These include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services and MedTech.
ARCHIMED’s value creation approach focuses on accelerating the growth of profitable healthcare leaders through international expansion, innovation, operational scaling and an active buy-and-build strategy.
“Investors like our healthcare specialization, top-decile DPI track-record, our proven alpha-focused Playbook, the well-structured and scalable platform, and our transparent governance and stable ownership.”
Denis Ribon, Chairman and Managing Partner at ARCHIMED
Since inception, the smallcap MED fund series has built on a robust performance history. Raising €146 million over 2014 and 2015, MED I, now fully realized, delivered a 7.2x multiple on invested capital and a 59% gross annualized return. Raising €315 million in 2018, MED II (50% realized) already shows a 3.1x MOIC and 33% annualized return (as of Q2 2026). The €650 MED III fund, closed in 2021, is a top quartile performer for its vintage year, as are all ARCHIMED funds, according to data from Preqin.